CD4+CD25+/highCD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints—analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood by Babak Moradi et al.
Moradi et al. Arthritis Research & Therapy 2014, 16:R97
http://arthritis-research.com/content/16/2/R97RESEARCH ARTICLE Open AccessCD4+CD25+/highCD127low/− regulatory T cells are
enriched in rheumatoid arthritis and osteoarthritis
joints—analysis of frequency and phenotype in
synovial membrane, synovial fluid and peripheral
blood
Babak Moradi1*, Philipp Schnatzer1, Sébastien Hagmann1, Nils Rosshirt1, Tobias Gotterbarm1, Jan Philippe Kretzer1,
Marc Thomsen2, Hanns-Martin Lorenz3, Felix Zeifang1 and Theresa Tretter3Abstract
Introduction: CD4+CD25+/highCD127low/− regulatory T cells (Tregs) play a crucial role in maintaining peripheral
tolerance. Data about the frequency of Tregs in rheumatoid arthritis (RA) are contradictory and based on the
analysis of peripheral blood (PB) and synovial fluid (SF). Because Tregs exert their anti-inflammatory activity in a
contact-dependent manner, the analysis of synovial membrane (SM) is crucial. Published reports regarding this
matter are lacking, so we investigated the distribution and phenotype of Tregs in concurrent samples of SM, SF
and PB of RA patients in comparison to those of osteoarthritis (OA) patients.
Methods: Treg frequency in a total of 40 patients (18 RA and 22 OA) matched for age and sex was assessed by
flow cytometry. Functional status was assessed by analysis of cell surface markers representative of activation,
memory and regulation.
Results: CD4+ T cells infiltrate the SM to higher frequencies in RA joints than in OA joints (P = 0.0336). In both
groups, Tregs accumulate more within the SF and SM than concurrently in PB (P < 0.0001). Relative Treg frequencies
were comparable in all compartments of RA and OA, but Treg concentration was significantly higher in the SM of
RA patients (P = 0.025). Both PB and SM Tregs displayed a memory phenotype (CD45RO+RA−), but significantly
differed in activation status (CD69 and CD62L) and markers associated with Treg function (CD152, CD154, CD274,
CD279 and GITR) with only minor differences between RA and OA.
Conclusions: Treg enrichment into the joint compartment is not specific to inflammatory arthritis, as we found that
it was similarly enriched in OA. RA pathophysiology might not be due to a Treg deficiency, because Treg
concentration in SM was significantly higher in RA. Synovial Tregs represent a distinct phenotype and are activated
effector memory cells (CD62L−CD69+), whereas peripheral Tregs are resting central memory cells (CD62L+CD69−).* Correspondence: babak.moradi@med.uni-heidelberg.de
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Table 1 Characteristics of the study populationa
Characteristics RA OA
Number of patients (M/F) 18 (11/7) 22 (13/9)
Age (yr) 67.5 ± 8 66.7 ± 8.3
Duration of disease (yr) 14 ± 7 15 ± 6
DAS28 score 4.5 ± 1.2 n.a.
RF-positive, n (%) 10 (55.6) n.a.
CRP (mg/L) 17 ± 9 5.1 ± 3
ESR (mm/h) 23 ± 12 4 ± 2
DMARD, n (%) 14 (77.8) 0
Anti-TNF treatment, n (%) 5 (27.8) 0
Glucocorticoids, n (%) 1 (5.6) 0
NSAID, n (%) 16 (88.9) 20 (90.1)
aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; DMARD,
Disease-modifying antirheumatic drug; ESR, Erythrocyte sedimentation rate;
n.a., Not applicable; NSAID, Nonsteroidal anti-inflammatory drug; OA,
Osteoarthritis; RA, Rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour
necrosis factor. Values are mean ± SD unless otherwise indicated.
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Rheumatoid arthritis (RA) is an autoimmune disease char-
acterized by a chronic relapsing–remitting inflammation
primarily of peripheral joints. The tissue-destructive inflam-
mation affects all joint structures, leading eventually to total
joint destruction. The pathology of the disease is character-
ized by disturbed immune regulation with predominance of
inflammatory cells on the one hand and defective periph-
eral immune tolerance on the other [1]. These immuno-
pathologic events occur predominantly within the joints
and particularly in the synovial membrane (SM) as the
main site of mononuclear cell infiltration. CD4+ T cells
comprise a large proportion of the inflammatory cells re-
cruited into the RA synovium and contribute significantly
to synovial inflammation [2]. In contrast to these inflamma-
tory CD4+ T cells, another T-cell subset, known as naturally
occurring regulatory T cells (Tregs), has been shown to play
an essential role in establishing the balance between pro-
and anti-inflammatory mechanisms in the periphery and
maintaining self-tolerance, both in rodents and in humans
[1,3-5]. The ability of Tregs to suppress T-cell responses,
and thereby to regulate immune reactions, ascribes to them
a key role in the pathophysiology of autoimmune diseases
and makes them an interesting target for treatment [2,6,7].
The suppressive capacity of human CD4+ T cells was first
shown to be contained within CD4+ cells expressing high
levels of CD25, the α chain of the IL-2 receptor [8]. Previ-
ous research has demonstrated that low expression of the
IL-7 receptor α chain (CD127), in combination with CD25,
allows the consistent and specific identification of viable
CD4+CD25+/highCD127low/− Tregs and facilitates their dis-
crimination from activated CD4+CD25+CD127+ effector T
cells [9-11]. Researchers in a number of studies have ana-
lysed the presence of Tregs in RA [12-21]. Apart from
contradicting results regarding the analysis of peripheral
blood (PB), accumulating evidence indicates that Tregs
are enriched in the synovial fluid (SF) of RA joints
[12-15,17,18,20]. In contrast, the presence and phenotype
of Tregs in the immunological organ of the joint, the SM,
remains largely unstudied. This is of special interest be-
cause Tregs develop their suppressive capacity in a contact-
dependent manner [8,9,14]. Researchers in only two studies
have analysed synovial biopsies and suggested a much
lower frequency of Tregs in synovial tissue than in SF
[18,20]. These immunohistochemical and quantitative PCR
analyses provide preliminary insight into Treg distribution,
but the techniques utilized do not allow further phenotypic
analysis of synovial Tregs and limit comparability to SF and
PB quantitative flow cytometry data. Furthermore, the com-
parison to equivalent samples from non-autoimmune-
driven joint disease is missing. These data are essential to
understanding RA-specific pathophysiology.
In our present study, we examined the frequency and
phenotypes of CD4+CD25+/highCD127low/− Tregs in thethree compartments (PB, SF and SM) of RA patients in
order to map the distribution of Tregs between the per-
iphery and the target organ. The data derived from RA
patient samples were compared to those from age- and
sex-matched samples of patients with OA as a nonau-
toimmune control group. To the best of our knowledge,
this study is the first to show that Treg enrichment into
the joint is not specific to inflammatory arthritis. RA
pathophysiology is probably not due to a lack of Tregs,
because Treg concentration in the SM of RA was signifi-
cantly higher than in OA. Furthermore, we show that
peripheral and synovial Tregs show significant differ-




The characteristics of the study population are sum-
marised in Table 1. RA and OA were determined accord-
ing to the 1987 criteria of the American Rheumatism
Association [22]. None of the OA patients had signs of a
systemic inflammatory disease based on analysis of CRP
and leukocyte counts. All patients were scheduled for knee
replacement surgery. The ethics committee of the Univer-
sity of Heidelberg approved this study. Informed consent
for participation was obtained from all patients.
Sample collection
SF and SM samples from knee joints were collected dur-
ing knee surgery. SF was removed prior to arthrotomy
by needle aspiration into ethylenediaminetetraacetic
acid (EDTA)–containing tubes (Sarstedt, Nümbrecht,
Germany). SM was taken from the suprapatellar pouch
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and collected in EDTA-containing tubes prior to surgery.
Cell preparation
SF samples were treated with bovine testicular hyaluroni-
dase (10 mg/ml; Sigma-Aldrich, St Louis, MO, USA) for
30 minutes at 37°C, and cells were washed twice with
phosphate-buffered saline (PBS). Single SM samples were
freed from other tissue components and rinsed twice with
PBS. SM was then minced finely with scissors and digested
with collagenase B (1 mg/ml; Roche Applied Science, In-
dianapolis, IN, USA) and bovine testicular hyaluronidase
IV (2 mg/ml) at 37°C for 2 hours in RPMI 1640 culture
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10 μg/ml penicillin/streptomycin (Invitrogen) 10%
foetal calf serum (Biochrom AG Biotechnologie, Berlin,
Germany). The cell suspension was filtered through a 100-
μm filter (BD Biosciences, San Diego, CA, USA) and a 40-
μm-pore-size sieve (EMD Millipore, Billerica, MA, USA)
to remove any undigested tissue. The filtered cell suspen-
sion was washed twice with PBS. Mononuclear cells
(PBMCs, SFMCs and SMMCs) were isolated from EDTA
anticoagulated whole blood, SF and SM cell suspension
samples using Ficoll-Paque™ PLUS density gradient centri-
fugation (GE Healthcare Life Sciences, Pittsburgh, PA,
USA). T cells were isolated from PB, SF and SM mono-
nuclear cells by MACS bead separation (CD3 MicroBeads;
Miltenyi Biotec, San Diego, CA, USA) based on previously
described protocols [13]. The volume and weight of all
samples were measured, and total cell numbers were de-
termined after mononuclear cell separation and CD3
isolation.
Flow cytometry analysis
Multicolour flow cytometry was used to identify the T-cell
subsets and expression of cell surface markers. All mono-
clonal antibodies (mAbs) were obtained from BD Bio-
sciences unless stated otherwise. In brief, MACS bead
separation–isolated T cells were washed twice in staining
buffer, blocked with FcR blocking reagent (Miltenyi Bio-
tec) and then stained for 30 minutes at 4°C with fluores-
cein isothiocyanate (FITC)–labelled mAb against CD4
(clone RPA-T4), phycoerythrin (PE)-labelled mAb against
CD25 (clone M-A251) and peridinin chlorophyll protein
complex cychrome 5.5 (PerCP-Cy5.5)–labelled mAb against
CD127 (clone RDR5; eBioscience, San Diego, CA, USA).
For intracellular staining, cells were stained for cell surface
markers with CD4-FITC, CD25-allophycocyanin (CD25-
APC) (clone 2A3) and CD127-PerCP-Cy5.5, then fixed
and permeabilised with the human FoxP3 buffer set (BD
Biosciences) according to the manufacturer’s instructions
and stained with PE-labelled mAb against FoxP3 (clone
259D/C7). The analysis of activation markers was per-
formed with PE-labelled mAb specific for one of thefollowing cell surface markers: CD45RA (clone HI100;
BioLegend, San Diego, CA, USA), CD45R0 (clone
UCHL1; BioLegend), CD69 (clone FN50), CD152 (cyto-
toxic T-lymphocyte antigen 4 (CTLA-4), clone BN13),
CD154 (CD40L; clone 89-76), CD274 (programmed cell
death receptor 1 ligand (PD-L1), clone 29E.2A3; BioLe-
gend), CD279 (programmed death receptor 1 (PD-1),
clone MIH4) and CD62L (L-selectin, clone DREG-56).
After being stained for surface molecules, the cells were
washed again and analysed with a FACSCalibur flow
cytometer (BD Biosciences). A total of 105 events were
collected and analysed using the FlowJo software pro-
gram (TreeStar, Ashland, OR, USA).
Gating strategy and definition of cell populations
Cells were gated for lymphocytes on the basis of for-
ward and side scatter profiles and further gated for CD4
expression. By using the cell surface markers CD25 and
CD127, the Treg population was identified as CD4+
CD25+/highCD127−/low Tregs. The cutoff for all cell surface
markers was established based on isotype controls. The
CD4+ cells with the highest level of CD25 staining were
defined as CD4+CD25high cells and appeared as a tail to
the right from the major CD4+ cell population, as previ-
ously shown [8]. The CD4+CD25+/highCD127−/low Treg
population was distinct and clearly separable from other
cells as previously described [9-11]. For the analysis of ac-
tivation markers, the CD4+CD25+/highCD127−/low Treg
population was gated as described previously and further
analysed for each PE-labelled cell surface marker. Expres-
sion of activation marker and mean fluorescence intensity
(MFI) was determined.
Statistical analysis
The demographic parameters of the OA and RA groups
were compared using an unpaired t-test for parametric
data (age and body mass index) and the χ2 test for propor-
tions (sex). The unpaired t-test was used for analysis of
Treg frequency between OA and RA groups, and the
paired t-test was used for comparisons between concurrent
PB, SF and SM samples. Differences in the expression
of activation markers were analysed by performing the
Mann–Whitney U test. Correlation analysis was performed
using the Pearson correlation coefficient. All P-values re-
ported herein are two-tailed. A P-value <0.05 was consid-
ered to show a statistically significant difference. Statistical
analysis was performed using GraphPad Prism version 5
software (GraphPad Software, La Jolla, CA, USA).
Results
Higher accumulation of CD4+ T cells in the affected joints
of rheumatoid arthritis patients
In order to assess T-cell distribution between the periph-
ery and the joints, we analysed the absolute cell counts
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by flow cytometry (Table 2). Within each study group,
comparison of PB with SF and SM revealed that PB con-
tained significantly higher concentrations of CD4+ T
cells. Furthermore, the concentration of CD4+ T cells
was significantly higher in the SM than in the SF. TheTable 2 Frequency of CD4+ T cells and CD4+CD25+/highCD127
synovial fluid and synovial membrane joint samples in rheum
RA OA
PB Sample size (n) 18 22
Sample volume (ml) 7 ± 0 7 ± 0
Concentration of CD4+ T cells (cells /μl) 730 ± 210 690 ± 90
(610 to 900) (540 to770)
CD4+CD25high (%total CD4+ T cells) 4.88 ± 2.04 4.4 ± 1.59
(2 to 9.4) (1.9 to 8)
CD4+CD25+/highCD127low/− (% total CD4+
T cells)
6.7 ± 1.8 7.6 ± 1.8
(4 to 11) (5 to 11)
CD4+CD25+/highCD127low/− (cells/μl) 48.9 ± 7.8 52.4 ± 4
(30 to 99) (29 to 85)
SF Sample size (n) 17 22
Sample volume (ml) 15.41 ± 12.65 11.21 ± 6.81
(4.3 to 38) (2.2 to 23.6)
Concentration of CD4+ T cells (cells/μl) 70 ± 170 40 ± 90
(30 to 540) (10 to 480)
CD4+CD25high (% total CD4+ T cells) 9.97 ± 6.27 9.63 ± 4.12
(3.4 to 19) (3.3 to 22.6)
CD4+CD25+/highCD127low/− (% total CD4+
T cells)
11.8 ± 5.5 12.4 ± 5
(5 to 22) (4 to 26)
CD4+CD25+/highCD127low/− (cells/μl) 8.3 ± 9.4 5 ± 4.5
(8to90) (4 to 100)
SM Sample size (n) 18 22
Sample volume (mg) 3.45 ± 1.18 3.72 ± 1.3
(2.2 to 5.9) (1.95 to 5.73)
Concentration of CD4+ T cells (cells/μg) 378 ± 250 240 ± 140
(10 to 610) (10 to 340)
CD4+CD25high (% total CD4+ T cells) 7.21 ± 3.9 7.5 ± 4.8
(2 to 18.4) (2.5 to 26)
CD4+CD25+/highCD127low/− (% total CD4+
T cells)
9.4 ± 3.8 11.2 ± 5.9
(5 to 17) (2.4 to 26)
CD4+CD25+/highCD127low/− (cells/μg) 35.5 ± 12 27 ± 11
(24 to 89) (14 to 73)
aOA, Osteoarthritis; PB, Peripheral blood; RA, Rheumatoid arthritis; SF, Synovial fluid
concentrations of CD4+ T cells are shown. Frequencies of CD4+CD25high and of CD4
for CD4+CD25+/highCD127low/− cells also as cell concentration (total cell counts per m
shown are mean ± SD (range) unless otherwise stated. bStatistically significant differcomparison between RA and OA revealed that the SM
of RA patients displayed a significantly higher accumula-
tion of CD4+ T cells than age- and sex-matched OA
controls (RA: 378 ± 250 cells/μg, OA: 240 ± 140 cells/μg;
P = 0.0336). No significant differences were observed in
SF and PB.low/− regulatory T cells in the peripheral blood and
atoid arthritis and osteoarthritis patientsa
P-values
RA:OA RA RA RA OA OA OA
PB:SF PB:SM SF:SM PB:SF PB:SM SF:SM
0.424 <0.0001b <0.0001b <0.0001b <0.0001b
0.417 0.0072b 0.0381b <0.0001b 0.004b
0.135 0.0006b 0.0128b 0.0001b 0.0091b
0.099 <0.0001b 0.0004b <0.0001b <0.0001b
0.479 <0.0001b 0.0001b <0.0001b <0.0001b
0.7371 0.0072b 0.2449 <0.0001b 0.1086
0.727 0.0006b 0.1226 0.0001b 0.4549
0.153 <0.0001b <0.0001b <0.0001b <0.0001b
0.0336b <0.0001b 0.0001b <0.0001b <0.0001b
0.8354 0.0381b 0.2449 0.004b 0.1086
0.266 0.0128b 0.1226 0.0091b 0.4549
0.025b 0.0004b <0.0001b <0.0001b <0.0001b
; SM, Synovial membrane. Collected sample volumes and calculated
+CD25+/highCD127low/− cells are shown as the percentage of CD4+ T cells and
icrolitre or per microgram) for PB, SF and SM in RA and OA patients. Values
ences.
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peripheral blood of RA and OA patients
We evaluated the frequency of CD4+CD25+/highCD127−/low
Tregs by flow cytometry (Figure 1). Intracellular FoxP3
staining of the CD4+CD25+/highCD127−/low cells was per-
formed in four patients, which revealed that the gated cells
were highly positive for FoxP3, as shown in Figures 2d to
2f (PB: 91 ± 4%, SF: 94 ± 8%, SM: 90 ± 7%). We analysed the
relative frequency of Tregs and plotted these data as the
percentage of CD4+ T cells and the absolute Treg count,
which are given as the concentration for each compartment
in Table 2. The relative and absolute frequencies of CD4+
CD25+/highCD127−/low Tregs in the peripheral blood of RA
and OA patients were comparable, without any significant
differences. In order to allow comparability to previous








































Figure 1 Flow cytometry analysis of CD4+CD25+/highCD127low/− regula
osteoarthritis patients. Peripheral blood (PB), synovial fluid (SF) and synov
after staining with fluorescein isothiocyanate (FITC)–labelled monoclonal an
against CD25 (clone M-A251) and peridinin chlorophyll protein complex cy
Representative dot plots for one RA patient and one OA patient are shown
forward and side scatter properties and further for CD4+ cells by positive a
the second columns indicate the CD4+CD25+/highCD127low/− regulatory T c
population in the first columns of each patient group.cells as shown in Figures 2d to 2f. The same pattern was
shown when gated for CD4+CD25high cells (Table 2).
CD4+CD25+/highCD127−/low Tregs are enriched in joints of
RA and OA patients
We further analysed SF and SM samples of the same pa-
tients in order to map the distribution of Tregs between
periphery and the affected joints. CD4+CD25+/high
CD127−/low Tregs were significantly enriched in the SF
and SM joint samples of both patient groups in compari-
son to PB (Table 2), with SF displaying the highest per-
centage of CD4+CD25+/highCD127low/− Tregs, followed by
SM and then PB. No significant differences between RA
and OA Treg percentages were evident for the three com-
partments. Gating for CD4+CD25high cells led to smaller





































tory T cells in all compartments from rheumatoid arthritis and
ial membrane (SM) CD4+ T cells were analysed by flow cytometry
tibody (mAb) against CD4 (clone RPA-T4), phycoerythrin-labelled mAb
chrome 5.5–labelled mAb against CD127 (clone RDR5; eBioscience).
. The cells in these analyses were gated for lymphocytes via their
nti-CD4-FITC staining (first column for each group). The red gates in
ells. These cells are back-gated and shown as the red CD4+CD25+/high


















































Figure 2 FoxP3 expression of CD4+CD25+/highCD127low/− T cells in different compartments and gating strategy for CD25high cells.
Samples were stained with anti-CD4–fluorescein isothiocyanate (FITC) (clone 2A3), anti-CD25–allophycocyanin (APC) (clone RDR5) and
anti-CD127–peridinin chlorophyll protein complex cychrome 5.5 (anti-CD127-PerCP) (clone RDR5) to identify CD4+CD25+/highCD127low/−cells.
After undergoing fixation and permeabilisation, cells were further stained with phycoerythrin-labelled FoxP3 (clone 259D/C7). The cells in these
analyses were gated for CD4+CD25+/highCD127low/−regulatory T cells, as shown in Figure 1. Cells stained with isotype controls are shadowed in
the histograms. The boldface line represents the FoxP3+ T cells. Four samples were analysed for each compartment. Representative histograms
for (a) peripheral blood (PB), (b) synovial fluid (SF) and (c) synovial membrane (SM) are shown. The numbers in the histograms indicate the
percentage of gated cells expressing FoxP3+. (d) to (f) Staining pattern for CD4-FITC and CD25-APC is shown. Representative dot plots of one
patient are shown. Gated areas indicate the CD25high cell populations in (d) PB, (e) SF and (f) SM.
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two study groups remained the same. Regarding total Treg
numbers, the highest Treg concentration in both groups
was present in PB, followed by SM and then SF, which is
due to the higher CD4+ T-cell count in these compart-
ments. The comparison between the two groups showed a
significantly higher Treg concentration in the SM of RA
patients (P = 0.025).
Correlation analysis of Treg frequencies between
compartments and with clinical data
In order to map Treg compartmentalization and analyse
the relationship between the PB and the joint compart-
ment, we performed correlation analysis of Treg fre-
quency. Only small correlations were detectable between
PB and SF or SM (r = 0.145 to 0.154, respectively), and
a medium correlation was found between SF to SM(r = 0.263 to 0.424), but these correlations were not
significant (P = 0.059 to 0.361, respectively). We found
no significant correlation between Treg frequency and
activation markers and clinical parameters, such as
sociodemographic and laboratory parameters, disease
activity and medication.
Phenotype analysis of CD4+CD25+/highCD127low/− Tregs in
RA and OA patients
A panel of cell surface markers was selected to
characterise the phenotype and activation status of
joint-derived Tregs (SF and SM) in comparison to cor-
responding cells from PB in both patient groups
(Table 3, Additional file 1: Table S1, and Figure 3). SF-
and SM-derived Tregs displayed the same phenotype as
that described in Table 3, which is why the comparison
described next focuses on the analysis of PB and SM





PB SF SM PB SF SM RA OA PB SM
PB:SM PB:SM RA:OA RA:OA
CD45RA 22.9 ± 5 5 ± 3 2.8 ± 1 34.9 ± 13.6 6 ± 3 5.6 ± 2.5 0.0059b 0.0006c 0.0631 0.2377
21 (19.5 to 30.2) 4 (3 to 7) 2.8 (2 to 3.5) 30.8 (16.8 to 57.4) 7 (2 to 9) 6 (2.1 to 8.8)
CD45RO 83 ± 14.7 93 ± 7 94.7 ± 5.2 81.4 ± 8.5 92 ± 8 91.9 ± 7.2 0.4 0.0232b 0.9554 0.6488
81 (70 to 99) 92 (87 to 99) 94.9 (89.4 to 99) 82 (60 to 95) 91 (81 to 98) 94.3 (80.9 to 99.8)
CD69 3.1 ± 1.9 88 ± 2 84.8 ± 0.2 1.9 ± 0.8 82.3 ± 5.3 81.2 ± 4.8 < 0.0001c 0.0029d 0.1623 0.4746
2.1 (1.9 to 5.2) 85 (80 to 92) 84.6 (78 to 89) 1.8 (0.9 to 3.7) 84 (77.3 to 88) 82.6 (74.6 to 84.9)
CD62L 94.6 ± 1.8 5 ± 2 2 ± 1 94.7 ± 4.4 3 ± 1 3.1 ± 0.5 < 0.0001c 0.0293b 0.8881 0.2480
94.5 (93.3 to 95.8) 3 (3 to 9) 2 (1.1 to 3.2) 95.3 (80.5 to 99.7) 3.5 (2 to 5) 3.1 (2.8 to 3.5)
CD152 12.6 ± 14 29.2 ± 12 36.2 ± 3.3 13 ± 6.5 31.5 ± 11 32.5 ± 8.2 0.0477b 0.0049d 0.7552 0.8530
5.7 (3.2 to 28.8) 33 (33 to 40) 36 (33 to 39) 16.3 (1 to 19) 30 (24 to 41) 32.5 (25 to 39.6)
CD154 13.5 ± 6.3 11 ± 5.7 15.1 ± 8.8 8.8 ± 5.4 12 ± 8 13.4 ± 8.2 0.5892 0.2863 0.2361 0.8486
13.4 (7 to 19.5) 13 (6 to 18) 15.1 (7 to 23) 8.5 (1.4 to 19) 11 (5 to 20) 10 (7.5 to 18)
CD274 23.5 ± 2.8 25 ± 7 27.6 ± 5.7 9.8 ± 10.4 25 ± 7 24.1 ± 7.9 0.3758 0.0313b 0.0329b 0.5541
23 (21 to 26) 32 (20 to 29) 31 (21 to 31) 6 (0.5 to 40) 26 (17 to 34) 24.1 (17 to 30.9)
CD279 3.3 ± 3.3 23.2 ± 12 22.6 ± 11 5.4 ± 6.5 9 ± 9 7.9 ± 10 0.0231b 0.6677 0.8127 0.0239b
3 (0.2 to 6.7) 24 (14 to 32) 22.6 (15 to 30.1) 2.2 (0 to 23.1) 8 (2 to 15) 8 (0.8 to 15)
GITR 30.3 ± 22.7 42.5 ± 7.3 45.5 ± 6.8 40.5 ± 12.8 49.2 ± 12 47.4 ± 11.9 0.329 0.173 0.636 0.8114
31.4 (7 to 52.4) 43 (39 to 51) 45.1 (38.9 to 52) 43.8 (18.4 to 59.1) 13.9 (33 to 59) 11.94 (30 to 58.7)
aGITR, Glucocorticoid-induced tumour necrosis factor receptor–related protein; OA, Osteoarthritis; PB, Peripheral blood; RA, Rheumatoid arthritis; SF, Synovial fluid; SM, Synovial membrane. Significant differences:
bP < 0.05; cP < 0.001; dP < 0.01. CD4+CD25+/highCD127low/− regulatory T cells from PB, SF and SM were stained for cell surface markers as indicated in the left column. The percentage of cells positive for each surface



























22.7 2.1 34.9 8.81
84.2 94.3 81 99.8
3.71 84.9 1.77 80.6
95.8 0.382 95.6 2.77
14.6 39.6 17.7 25.4
19 22.7 8.7 10
21.6 30.9 3.89 17.3
3.03 30.1 1.57 9.01
30.6 48.2 37.9 49.1
Figure 3 (See legend on next page.)
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Figure 3 Phenotype characteristics of CD4+CD25+/highCD127low/− T cells in rheumatoid arthritis and osteoarthritis patients in different
compartments. Samples were stained with anti-CD4–fluorescein isothiocyanate (clone 2A3), anti-CD25–allophycocyanin (clone RDR5), and
anti-CD127–peridinin chlorophyll protein complex cychrome 5.5 (clone RDR5) to identify CD4+CD25+/highCD127low/− cells. The cells were further
stained for the following surface markers: CD45RA (clone HI100; BioLegend), CD45R0 (clone UCHL1; BioLegend), CD69 (clone FN50), CD152
(cytotoxic T-lymphocyte antigen 4 (CTLA-4), clone BN13), CD154 (CD40L, clone 89-76), CD274 (PD-L1, clone 29E.2A3; BioLegend), CD279 (PD-1,
clone MIH4) and CD62L (L-selectin, clone DREG-56). Cells stained with isotype controls are shadowed in the histograms. The boldface line
represents the CD4+CD25+/highCD127low/− T cells. GITR, Glucocorticoid-induced tumour necrosis factor receptor; OA, Osteoarthritis; PB, Peripheral
blood; RA, Rheumatoid arthritis; SM, Synovial membrane.
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CD127low/− Tregs were memory cells. PB Tregs expressed
CD45RO in 83% of RA patients and 81.4% OA patients.
CD45RO is associated with proliferative responses to re-
call antigens. The opposite expression profile was evident
for CD45RA, which is a marker for naive T cells. In this
study, 22.9% of the PB CD4+CD25+/highCD127low/− Tregs
of RA patients expressed CD45RA, compared to 34.9% in
OA patients. This pattern was also evident for synovial
Tregs, with an even higher expression of CD45RO and a
significantly lower expression of CD45RA. Only a small
proportion of PB Tregs in RA and OA expressed CD69, a
common marker for early T-cell activation. In synovial
Tregs, CD69 expression significantly increased to about
80%, confirming higher T-cell activation, with only small
differences observed between the two patient groups. The
significantly higher activation status of synovium-derived
Tregs was further supported by the expression profile of
L-selectin (CD62L). CD62L was expressed by about 90%
of PB Tregs in both patient groups and decreased sig-
nificantly in the SM samples to 2% in RA patients and
3.1% in OA patients (P = 0.0293 and P = 0.0001, respect-
ively). This finding was also confirmed by MFI (Additional
file 1: Table S1). The expression of CD152 (CTLA-4),
CD154 (CD40L), CD274 (PD-L1), CD279 (PD-1) and
glucocorticoid-induced tumour necrosis factor receptor
(GITR) were also evaluated in order to gain insight into
the regulatory function of Tregs. CD152, which displayed
only low expression levels in PB, increased significantly in
SM, with a slightly higher expression in RA patients than
in OA patients. The expression level of CD154 in PB
Tregs was low in both patient groups and increased
slightly in the SM, without any significant difference be-
tween RA and OA patients. We observed a significant in-
crease for SM in OA patients when analysed by MFI. In
PB, CD274 showed a significantly higher expression level
in RA patients (23.5%) than in OA patients (9.8 %) (P =
0.0329). In both groups, CD274 expression was increased
in synovial Tregs, diminishing the difference seen in PB.
The expression profiles of CD279 and GITR showed a
similar pattern, with increased expression in SM samples.
For CD279, this increase was found to be significant upon
comparing PB and SM of RA patients (P = 0.0231).Furthermore, synovial Tregs showed a significantly higher
expression of CD279 in RA patients than in OA patients
(P = 0.0239), which was also present when analysed for
MFI (P = 0.0421). No significant difference in GITR could
be detected between the patient groups.
Discussion
Data about the frequency of Tregs in PB of RA vary
throughout the literature, in which it is described as de-
creased [13,14,16,17,21], similar [12,15] and increased
[14,19] compared to healthy controls. This controversy is
partly due to the lack of one specific Treg marker and the
resulting differences in the identification of Tregs (CD25+
vs. CD25high). The transcription factor FoxP3, which is re-
quired for Treg development, has improved the specificity
of Treg detection, but its intracellular location does not
allow separation of viable cells [23]. The establishment of
CD127 as an additional surface marker, in combination
with CD25, has been found to facilitate a consistent quan-
titative identification of viable CD4+CD25+/highCD127low/−
Tregs, which are highly positive for FoxP3 [9-11]. Only
one previous study has provided quantitative data regard-
ing CD4+CD25+/highCD127low/− Tregs in the PB of RA pa-
tients. The investigators showed lower frequency in active
RA and similar Treg frequency in RA patients in remis-
sion compared to controls [21]. In our present study, the
mean frequency of CD4+CD25+/highCD127low/− Tregs in
PB samples was comparable between RA and OA patients.
It seems that the analysis of circulating Tregs has not de-
scribed the disease-specific parameters consistently enough
to draw conclusions. This raises the question whether the
analysis of Treg frequency at the site of inflammation
might provide a clearer pattern of RA pathology. Re-
searchers in a few studies have analysed the SF of affected
RA joints and showed an increase in Treg frequency
compared to PB samples taken concurrently from those
patients and healthy controls [12-15,17,20,24]. This accu-
mulation into the affected RA joints ran counter the
hypothesis of a reduced Treg presence in RA patho-
physiology. But due to the lack of SF control samples in
these studies, it remained unresolved if the increase of
Treg frequencies in RA SF might turn out as a reduced
frequency when compared to non-RA SF controls. The
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the first time that Treg enrichment into the joints is not a
feature specific to RA, but is also present in the joints of
nonautoimmune OA patients. Furthermore, our data dis-
prove the hypothesis of a lack of Tregs in RA because we
show that Treg frequency in SF is comparable between
RA and OA patients. The fact that Tregs develop their
suppressive activity in a contact-dependent manner, as
well as that soluble factors alone are unable to exert sup-
pression, highlights the relevance of further investigation
of the SM [8,9,14]. Only two studies have analysed the SM
for the presence of FoxP3 by immunohistochemistry and
qPCR [18,20]. Those two studies have suggested a much
lower frequency of Tregs in SM than in SF and PB, favour-
ing the hypothesis that, in RA patients, the SM lacks suffi-
cient Treg numbers and thus these patients would benefit
therapeutically from an increase in Tregs. In order to fur-
ther evaluate this hypothesis, we analysed concurrent sam-
ples of SM from RA and OA patients and provide for the
first time flow cytometry–derived quantitative data. Our
results are contradictory to the common assumption that
Treg frequency is lower in SM than in PB. Both groups in
our study exhibited significant enrichment of Tregs in the
SF and SM compared to concurrent PB. When analysed
for absolute Treg numbers, the SM showed a significantly
higher Treg concentration than SF in OA and RA pa-
tients. Additionally, the comparison to OA samples re-
vealed that Treg concentration is significantly higher in
the SM of RA patients. Our results indicate that Treg defi-
ciency is not the underlying mechanism of RA develop-
ment. Instead, the significantly higher CD4+ T-cell
infiltration of RA joints suggests that Tregs are either
counterbalanced by effector T cells in the joint or func-
tionally impaired. Herrath et al. recently showed that the
inflammatory milieu in RA joints reduces the ability of
Tregs to cope with the overwhelming number of inflamma-
tory cells [24]. This favours the hypothesis that the suppres-
sive activity of Tregs can be altered and counterbalanced by
activated responder T cells in the joint, which are less sus-
ceptible to suppression as their counterparts from PB [14].
The discrepancy between our results and those re-
ported in the previous two studies might be due to fac-
tors such as study population, sample collection and
utilization of different techniques. Apart from the older
age of our study population, the demographics and clin-
ical parameters of our study are comparable to those of
these previous studies [18,20]. We received all samples
at the time of joint surgery, which differs from the study
of Raghavan et al., who collected SF samples mainly dur-
ing RA flares [20]. How this can affect Treg frequency
and status remains unknown. In studies comprising
longitudinal samples taken from patients with psoriatic
arthritis, spondyloarthropathy and juvenile idiopathic
arthritis, the frequency of Tregs was found to berelatively stable between flares and remissions [10,12,13].
The two-dimensional character of immunohistochemistry
and the analysis of tissue slices provides information about
a rather limited cell number. The distribution of infiltrat-
ing cell populations appears not to be homogeneous
throughout the joint. Regions with high inflammatory in-
filtrates might lead to an underestimation of Tregs due to
an overrepresentation of total CD4+ T cells. In our present
study, flow cytometry was the method of choice because it
allows for determination of mean frequency of distinct cell
populations and the simultaneous analysis of the expres-
sion of multiple surface markers in individual cells. Even
qPCR does not allow examination of individual cells and a
combination of markers.
One underlying hypothesis about Treg enrichment
into the affected joints of RA and other inflammatory
diseases is that Tregs are either attracted or generated
because of ongoing inflammation [25]. Because our re-
sults demonstrate that Treg enrichment is also evident
in OA joints, this hypothesis needs reevaluation. It could
be argued that OA pathology is also accompanied by
low-level chronic synovial inflammation [26]. Taking this
into account, the accumulated Treg presence in the
joints of both patient groups can be understood as an at-
tempt of the immune system to control the inflamma-
tory responses. The faster and much more severe
progression of joint destruction in RA could be due to
the complex inflammatory environment that might lead
to impaired Treg function.
Another hypothesis is that compartmentalization rather
than inflammation is the driving force. The physiology of
the joint compartment differs from the periphery, and
Treg compartmentalization has been shown to be tissue-
and organ-specific [17,27]. The low correlation between
PB, SF and SM Treg frequency in our study suggests that
distinct mechanisms contribute to selective retention and
trafficking of Tregs and that the SF and SM cannot be
expected to mirror the PB. We hypothesize that the
joint compartment contains a higher polarized CD4+
T-cell population and, as such, also a higher Treg popu-
lation compared to PB, where the majority of T cells are
naïve and not yet polarized into subsets. Assuming this
is true, future studies need to include the simultaneous
analysis of inflammatory T-cell subsets in order to map
the compartmentalization of effector and regulatory
T cells and analyse their balance in the periphery and
the joint.
The fact that the joint compartment differs significantly
from the periphery became even more evident when the
phenotypic analysis of Tregs was performed. In accord
with the results of previous studies, our data confirm that
peripheral Tregs display a CD45RO+CD45RA− memory
phenotype [12,28]. This was further increased in SM
Tregs, where almost all Tregs presented a memory
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and the joint were also observed when analysed for activa-
tion markers CD69 and CD62L. SM Tregs were CD62L
−CD69+ activated effector memory cells compared to
CD62L+CD69− resting central memory Tregs in PB. Sig-
nificant differences were also seen for markers associated
with Treg function. CD152 is thought to be essential for
the suppressive ability of Tregs [29,30]. Peripheral Tregs
constitutively express low surface levels of CD152, with in-
creased and long-lasting expression after stimulation
[6,7,14,15,30-33]. In accord with these findings, our data
display low expression of surface CD152 in PB, which was
significantly increased in the SM, confirming the activated
state of synovium-derived Tregs [14]. Murine and human
studies have attributed a relevant role for GITR in Treg
function, where antibody binding abrogates suppression
[34,35]. Our data are in accord with those of previous
studies in which researchers have shown low expression of
GITR in the periphery [14] and a significant increase in
synovial Tregs [6,7,31-34]. Since the intensity of GITR ex-
pression has been correlated with the suppressive capacity
of the Treg cells [33], the higher expression on synovium-
derived Tregs could indicate a higher suppressive capacity
of synovial Tregs. The programmed death receptor 1 (PD-1)
CD279 is involved in the mechanism of cell-cycle arrest
[5,30,36,37]. Its ligand CD274 (PD-L1) was recently shown
to deliver a negative signal through the PD-1 receptor,
which downregulates T-cell proliferation and cytokine pro-
duction [38,39]. When analysed in PB, the expression level
of CD279 or CD274 did not show any significant difference
between RA and OA patients, with low expression levels for
both. CD274 showed a significant increase in SM Tregs in
both groups, whereas CD279 increased only in the SM of
RA patients. Further analyses are necessary to evaluate how
these expression levels translate into functional differences
between Tregs from different compartments and between
RA and OA patients.
Conclusions
Our data show that CD4+ T cells are significantly enriched
in the SM of RA patients when compared to OA. CD4+
CD25+/highCD127low/− Tregs accumulation in the affected
joints is not disease specific for RA but also evident in
OA. Thus, the comparison and normalization of the quan-
titative data to OA levels is necessary in order to under-
stand RA disease specific pathology, which is the strength
of this study. Since relative Treg frequencies did not differ
significantly between RA and OA and the Treg concentra-
tion in RA SM samples was even significantly higher than
in OA, we hypothesize that Treg deficiency is not the
underlying mechanism in RA. The significant higher
CD4+ T cell infiltration of RA joints rather suggests that
Tregs are either functionally impaired or counterbalanced
by effector T cells in the joint, which may become Tregresistant. Phenotype analysis revealed significant differ-
ences between PB and SM Tregs showing that synovial
Tregs are activated memory cells compared to resting
memory cells in the PB. This underlines the importance of
analysing samples from the affected joints and most im-
portantly the SM as the target organ, when studying RA
pathophysiology. We think that the simultaneous assess-
ment of synovial effector T-cells and Tregs and their func-
tional properties are pivotal for the understanding or RA
pathophysiology. Our results demonstrate for the first
time that flow cytometric identification of viable synovial
Tregs according to surface marker expression is possible
and this opens new avenues for their use in functional
studies.
Additional file
Additional file 1: Table S1. Mean fluorescence intensity of activation
markers of CD4+CD25+/highCD127low/− T cells from peripheral blood,
synovial fluid and synovial membrane of rheumatoid arthritis and
osteoarthritis patients. CD4+CD25+/highCD127low/− regulatory T-cells from
peripheral blood (PB), synovial fluid (SF) and synovial membrane (SM)
were stained for cell surface markers as indicated in the left column.
Mean fluorescence intensity for each surface marker is presented as
mean ± SD or median and range. Data are representative of three
rheumatoid arthritis (RA) to five osteoarthritis (OA) patients. Statistical
analysis are shown for PB and SM because SF values did not differ from
SM values. Significant differences are indicated by asterisks: *P < 0.05;
**P < 0.01.
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